Journals / MN Oftalmoloji / 2016 / Cilt: 23 - Sayı: 1

An Early Diagnosed Tamoxifen Retinopathy Case

Erken Dönemde Tespit Edilen Tamoksifen Retinopatisi

Pages
62–65
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tamoxifen retinopathy should be kept in mind even in low-dose (20 mg/day) therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 51-year-old female patient who has been followed up for three years for breast cancer presented to our clinic with the complaint of decreased vision and metamorphopsia for a few months.
📊
Key Findings & Data:The patient was using tamoxifen 20 mg/day for 2 years.
💡
Conclusion & Impact:Tamoxifen retinopathy should be kept in mind even in low-dose (20 mg/day) therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 51-year-old female patient who has been followed up for three years for breast cancer presented to our clinic with the complaint of decreased vision and metamorphopsia for a few months. The patient was using tamoxifen 20 mg/day for 2 years. Visual acuity was 0.6 in the right eye and 0.1 in the left eye on her ophthalmological examination. She had a history of amblyopia in her left eye. The anterior segment examination was normal in both eyes. The fundus examination revealed only retinal pigment epithelium (RPE) changes. Fluorescein angiography demonstrated a hyperfluorescence dot on fovea, starting at early stages and retaining shape in late frames. Optical coherence tomography showed irregular RPE. Bilateral peripheral scotomas were detected on Humphrey automated perimetry. The patient was diagnosed as early stage tamoxifen retinopathy and symptoms regressed after giving up tamoxifen treatment. Tamoxifen retinopathy should be kept in mind even in low-dose (20 mg/day) therapy.

Özet

Erken Dönemde Tespit Edilen Tamoksifen Retinopatisi Erkan ÇELİK*, Erdinç BOZKURT*, Burçin ÇAKIR*, Nilgün AKSOY*, Tural BABASHLI*, Gürsoy ALAGÖZ*Üç yıldır meme kanseri nedeni ile takip edilen 51 yaşında bayan hasta, son birkaç aydır görmede azalma ve çizgilerde kırılma yakınmasıile kliniğimize başvurdu. Hasta son 2 yıldır 20 mg/gün tamoksifen kullanıyordu. Hastanın yapılan muayenesinde görme keskinliği sağda 0,6,solda 0,1 düzeyinde idi. Sol gözde ambliyopi öyküsü mevcuttu. Biyomikroskopik muayenede her iki gözde ön segment doğal idi. Fundus muayenesinde sadece retina pigment epitel (RPE) değişikliği izlendi. Fundus flöresein anjiyografisinde sağ gözde foveal alanda erken dönemdebaşlayan ancak ilerleyen dakikalarda artış göstermeyen hiperflöresan bir nokta izlendi. Optik koherans tomografisinde her iki gözde RPE'dedüzensizlikler görüldü. Humphrey bilgisayarlı görme alanında her iki gözde periferik skotomları mevcuttu. Tamoksifen retinopatisi olarak değerlendirilen hastanın, tamoksifeni kesildi ve semptomlarında düzelme gözlendi. Düşük dozlarda uygulanan tamoksifen tedavisinin bile, retinopati oluşturabileceği akılda tutulmalıdır

🔖

Cite This Article

ÇELİK, E., BOZKURT, E., ÇAKIR, B., AKSOY, N., BABASHLI, T., ALAGÖZ, G. (2016). An Early Diagnosed Tamoxifen Retinopathy Case. MN Oftalmoloji, Cilt: 23 - Sayı: 1, 62–65. https://ajindex.com/articles/295670

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol 2007;144(1):126-8.
  2. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315-20.
  3. Eisner A, Luoh SW. Breast cancer medications and vision: Effects of treatments for early-stage disease. Curr Eye Res 2011;36:867- 85. Hager T, Hoffmann S, Seitz B. Unusual symptoms for tamoxifen- associated maculopathy. Ophthalmologe 2010;107(8):750-2. Toler SM. Oxidative stres plays an important role in the patho- genesis of drug-induced retinopathy. Exp Biol Med (Maywood) 2004;229(7):607-15.
  4. Eisner A, Austin DF, Samples JR. Short wave length automated perimetry and tamoxifen use. Br J Ophthalmol 2004;88:125-30.
  5. Şendül SY, Üçgül C, Kurnaz Y, et al. Tunnel vision in visual field analysis after low dose tamoxifen treatment. Glo-Kat 2010; 5:124-6.